AIM
STML

Acrospire Investment Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Acrospire Investment Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-635
Closed -$7K – 2622
2016
Q4 		$7K Buy
+635
New +$7.68K ﹤0.01% 2023

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Acrospire Investment Management's STML Position: Q1 2017 in Review

Acrospire Investment Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2017, closing a stake of 635 shares — an estimated $7K sold.

Acrospire Investment Management first reported a position in STML in Q4 2016 and held it in 1 quarter. The position peaked at $7K in Q4 2016. 75 funds tracked by Wall St. Rank hold STML as of Q1 2017.

  • Acrospire Investment Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 635 Stemline Therapeutics, Inc. shares in Q1 2017, an estimated $7K.
  • Acrospire Investment Management first reported a position in Stemline Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Stemline Therapeutics, Inc. position peaked at $7K in Q4 2016.
  • 75 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.